World Media Directory · RSS · Email Newsletters

There were 2,260 press releases posted in the last 24 hours and 440,010 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

TO:

FROM:
Your Name:
Your Email:	Please check your email address!
Subject:
Message:
Confirmation code:	Please, do not fill this field.
Confirmation version code:	Please, do not change this field.
Javascript data:	Please, do not fill if your javascript is turned off.
Please type in the code you see in the image. Or click Send Email to generate another image instead.